Get started
Author

Matthew M. Riggs

Observed names: M. Riggs, MATTHEW RIGGS, MM Riggs, Matthew M Riggs, Matthew Riggs, Riggs, Matthew M
Observed institutions: Human Genome Sciences (United States), University of Connecticut, Bon Secours Health System, Cornell University, University of Utah, University of Michigan, Metrum Research Group (United States), Boehringer Ingelheim (Canada), Medical University of Vienna, James Cook University
ORCID: 0000-0001-5542-6058
Observed ORCIDs: 0000-0001-5542-6058, 0000-0001-5046-4434
OpenAlex ID: A5012025430
A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
2009 · Mark C. Peterson, Matthew M. Riggs · Bone · 208
Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences
2019 · Jörg Lippert, Rolf Burghaus, et al. · CPT Pharmacometrics & Systems Pharmacology · 119
PDF
Quantitative Systems Pharmacology and Physiologically‐Based Pharmacokinetic Modeling With mrgsolve: A Hands‐On Tutorial
2019 · Ahmed Elmokadem, Matthew M. Riggs, et al. · CPT Pharmacometrics & Systems Pharmacology · 95
PDF
FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?
2015 · MC Peterson, MM Riggs · CPT Pharmacometrics & Systems Pharmacology · 77
PDF
Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model
2012 · MC Peterson, MM Riggs · CPT Pharmacometrics & Systems Pharmacology · 58
PDF
Quantification of the Impact of Partition Coefficient Prediction Methods on Physiologically Based Pharmacokinetic Model Output Using a Standardized Tissue Composition
2020 · Kiersten Utsey, Madeleine S. Gastonguay, et al. · Drug Metabolism and Disposition · 48
PDF
Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis
2012 · MM Riggs, M Bennetts, et al. · CPT Pharmacometrics & Systems Pharmacology · 46
PDF
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes
2013 · Matthew M. Riggs, Alexander Staab, et al. · The Journal of Clinical Pharmacology · 34
Multiscale Physiology‐Based Modeling of Mineral Bone Disorder in Patients With Impaired Kidney Function
2012 · Matthew M. Riggs, Mark C. Peterson, et al. · The Journal of Clinical Pharmacology · 32
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
2016 · Kyle T. Baron, Sreeraj Macha, et al. · Diabetes Therapy · 26
PDF
A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial
2021 · Emmanuel Chigutsa, Eric Jordie, et al. · Clinical Pharmacology & Therapeutics · 23
Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data
2016 · Alanna S. Ocampo-Pelland, Marc R. Gastonguay, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 23
Population pharmacokinetics and exposure–response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2‐targeted regimens
2017 · Shang‐Chiung Chen, Angelica Quartino, et al. · British Journal of Clinical Pharmacology · 22
PDF
Facilitating pharmacometric workflow with the metrumrg package for R
2012 · Timothy T. Bergsma, William Knebel, et al. · Computer Methods and Programs in Biomedicine · 20
A Systematic Review of Large Agriculture Vehicles Use and Crash Incidents on Public Roads
2019 · Richard. C. Franklin, Jemma. C. King, et al. · Journal of Agromedicine · 19
Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, in patients with type 2 diabetes
2014 · Matthew M. Riggs, Leo J. Seman, et al. · British Journal of Clinical Pharmacology · 19
Training the next generation of pharmacometric modelers: a multisector perspective
2023 · Peter L. Bonate, Jeffrey S. Barrett, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 18
PDF
Pharmacometrics and systems pharmacology for metabolic bone diseases
2019 · Matthew M. Riggs, Serge Cremers · British Journal of Clinical Pharmacology · 15
Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model
2015 · RJ Eudy, MR Gastonguay, et al. · CPT Pharmacometrics & Systems Pharmacology · 14
PDF
A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis
2021 · Oliver Pohl, Kyle Baron, et al. · British Journal of Clinical Pharmacology · 13
PDF
Population Pharmacokinetic– Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus
2017 · John Mondick, Matthew Riggs, et al. · The Journal of Clinical Pharmacology · 13
Perspective on the State of Pharmacometrics and Systems Pharmacology Integration
2018 · Mirjam N. Trame, Matthew Riggs, et al. · CPT Pharmacometrics & Systems Pharmacology · 12
PDF
Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy
2019 · Bruce A. Perkins, Nima Soleymanlou, et al. · Diabetes Obesity and Metabolism · 11
PDF
A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis
2017 · Rena J. Eudy-Byrne, William Gillespie, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 11
Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
2022 · Katherine Kay, Justin Goodwin, et al. · Clinical Pharmacology & Therapeutics · 10
PDF
Works count: 53
Citation count: 1,060
H-index: 17
I10-index: 28
Year
Topic
Type